Call Me
Back
Phone Book Learn to Trade

[bwp-recaptcha bwp-recaptcha-93]

United Kingdom: +44 20 3773 8602
Sweden: +46812410070
Norway: +4721930512
New Zealand: +6448302404
Israel: +97223740103
Austria: +43720775041
Australia: +61280730589
Spain: +34933938161
South Africa: +27115682351
Canada: +14382289855
AUD/USD 0.79686 23:30 27.07 GBP/JPY 145.298 23:30 27.07 EUR/JPY 129.890 23:30 27.07 EUR/USD 1.16822 23:30 27.07 USD/JPY 111.182 23:30 27.07 NZD/USD 0.74956 23:00 27.07 AUD/NZD 1.06352 23:00 27.07 USD/JPY 111.232 22:30 27.07 BITCOIN 2648.744 22:00 27.07 EUR/USD 1.16753 22:00 27.07 USD/CHF 0.96480 21:00 27.07 USD/CAD 1.25536 21:00 27.07 GBP/USD 1.30655 21:00 27.07 EUR/GBP 0.89385 21:00 27.07 AUD/USD 0.79673 20:30 27.07 USD/CAD 1.25549 20:30 27.07 EUR/USD 1.16768 20:30 27.07 GBP/CHF 1.26068 20:30 27.07 GBP/USD 1.30624 20:15 27.07 TOYOTA (US) 111.700 20:00 27.07 ALIBABA 154.270 20:00 27.07 JOHNSON & JOHNSON 130.810 20:00 27.07 BANK OF AMERICA 24.115 20:00 27.07 WAL-MART 79.785 20:00 27.07 EUR/CHF 1.12626 20:00 27.07 JP MORGAN CHASE 91.545 20:00 27.07 AUD/CAD 1.00042 20:00 27.07 DOLLAR INDEX-APR17 93.770 20:00 27.07 McDONALD'S 156.965 20:00 27.07 EUR/CAD 1.46627 20:00 27.07

Market Review

DAILY MARKET OVERVIEW
Today's Top Market Headlines – Jan 26, 2017
Britain's economy beats forecasts with 0.6% growth in the last quarter

The Gross Domestic Product released by the National Statistics is a measure of the total value of all goods and services produced by the UK and it is considered as a broad measure of the UK economic activity. The quarterly GDP for the U.K. rose steadily by 0.6 percent. Britain’s service sector drove the most growth in the last quarter, expanding by 0.8%, while construction while industrial output lagged behind. Following falls in Quarter 3 (July to Sept) 2016, construction and production provided modest positive contributions to the GDP growth in Quarter 4 2016. Overall, UK GDP was estimated to have increased by 2.0% during 2016.  .

European Markets head higher on solid data…

European markets moved higher on Thursday morning extending yesterday’s profits that boosted the Dow Jones industrial average to an all-time high. Banking and healthcare stocks were the best performers as investors remained confident that President Donald Trump will carry on implementing his campaign pledges, including cutting taxes, business protectionism and de-regulation. It is also worth noting that the British Banker’s Association also announced Thursday that the number of mortgages approved by British bank hit a nine-month high in December.

Biotech shares advance in the face of the FDA decision next month

January has been a rather slow month in terms of drug approvals. Specifically, Synergy Pharmaceuticals Inc.’s (SGYP) Trulance for the treatment of Chronic Idiopathic Constipation in adult patients, and Allergan plc’s (AGN) Rhofade cream for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults were the only drugs that won the FDA’s green light in January. The iShares of Nasdaq Biotechnology ETF (IBB) added an impressive 4.7% this month, outperforming the S&P 500 by 43%.

Actelion shares skyrocket on a $30 billion takeover deal with JNJ

Shares of Actelion Ltd. skyrocketed by around 21 percent in the morning trading after the Swiss biotechnology firm on Thursday agreed to a $30 billion takeover by drug major Johnson & Johnson. Immediately prior to the completion of the acquisition, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly standalone Swiss biopharmaceutical company. Under the deal terms, Johnson & Johnson will launch a cash buyout offer in Switzerland to acquire Actelion for $280 per share, payable in U.S. dollars, which equates to 280.08 Swiss francs per share.